Orally administered tablets derived from the powdered API are normally screened first on a 10-station rotary press fitted with 12 mm round flat-faced punches and a forced feeder. The primary technical limitation encountered is not the chemical stability of the alkaloid markers but the rheological behaviour of the raw herbal matrix: residual moisture measured by USP <921> Method Ia above 6.0% w/w creates frequent sticking on the lower punch, while moisture below 3.0% w/w increases friability and lamination because the fibrous leaf/stem fragments undergo elastic recovery after decompression. Preformulation trials on a 300 kg batch scale typically set the API fraction by arithmetic dose adjustment rather than by fixed industrial rule: a 500 mg tablet requiring 100 mg of the powder API yields a 20% w/w drug load, whereas a 250 mg tablet with 50 mg API yields the same ratio. Above 30% w/w drug load, the bulk density of the blend falls below 0.45 g/cm³ measured by Ph. Eur. 2.9.34, and the angle of repose measured by USP <1174> exceeds 40°; under those conditions tablet weight variation approaches the acceptance limit of USP <905> before a sufficient compression force window can be established. Dry granulation with roller compaction at a roll pressure of 40–60 bar and a sieve cut of 0.8–1.25 mm is preferred when the API exceeds 30% w/w. Main compression forces between 12 kN and 22 kN produce tablets with crushing strength of 70–120 N determined by USP <1217>, provided the upper pre-compression force is limited to 5–8 kN to allow air escape from the compressible herb particles. Terminal tablet weight, hardness, disintegration time by Ph. Eur. 2.9.1, and loss on drying by USP <731> are recorded for each batch; disintegration below 15 minutes in water at 37 °C is used as a lot-release criterion for oral bolus tablets. The final tablet form is commonly a 5–10 mm scored veterinary oral tablet packed in aluminium/PVC blisters with desiccant. Tablets produced from the raw powder are unsuitable for parenteral use without further extraction.

What Capsule Fill Parameters Prevent Segregation in 100% Herbal API Powder Blends?

Encapsulation of the powder API on a tamping-pin capsule filler differs from tablet compression because the powder is not consolidated; segregation during hopper discharge and dosing disc transfer becomes the main failure mode. The fill material is typically prepared as a preblend of the milled herbal powder with a diluent and glidant, with the API fraction set by the required marker alkaloid intake per animal. A size 1 hard gelatin capsule filled to 0.50 g net fill weight can accommodate 125 mg of the API at a 1:3 API-to-diluent ratio; the diluent is usually lactose monohydrate or microcrystalline cellulose with particle size d90 below 250 µm by ISO 2591-1:2008. The inclusion of 0.5% w/w colloidal silicon dioxide and 0.5% w/w magnesium stearate is standard, but the order of addition is critical: magnesium stearate is added only after the API and diluent have been mixed for 15 minutes in a bin blender at 15 rpm to avoid hydrophobic film formation on the herb particles. Blend uniformity is evaluated by taking 10 sampling points and comparing marker alkaloid assay by Ph. Eur. 2.2.29 HPLC; acceptance is typically a relative standard deviation below 5.0% in accordance with USP <905> content uniformity principles. Capsule fill weight variation on a tamping-pin machine is controlled by pin penetration depth and bed height; a fill weight relative standard deviation below 3.0% is required to ensure the final capsule reaches the labelled dose. Moisture is kept below 5.0% w/w by USP <921> to prevent capsule shell brittleness in low-humidity packaging; capsule equilibration at 40–50% relative humidity is used before filling. Terminal capsules are tested for disintegration by Ph. Eur. 2.9.1 with water at 37 °C, with a limit of 30 minutes for hard capsules. The finished capsule format is typically packed in HDPE bottles with tamper-evident caps and a desiccant canister for farm storage. Powders for capsules are not terminally sterilised; the microbiological specification follows Ph. Eur. 5.1.4 or the relevant veterinary pharmacopoeial monograph.

When Aqueous Parenteral Use Demands Endotoxin Control Below 0.5 EU/mg in Herbal Solutions

For injectable solutions, the raw dried powder is subjected to aqueous extraction rather than direct dissolution. A typical extraction ratio of 1:10 w/v dried powder to purified water is heated to 80–90 °C for 60 minutes under reflux, then clarified by centrifugation at 3,000×g and by 0.45 µm membrane filtration before sterile filtration. The resulting solution is adjusted to a total solids concentration of 10 mg/mL and pH 5.5–6.5 with dilute hydrochloric acid or sodium hydroxide to keep the alkaloid markers in stable salt form; the pH range is selected because precipitation of basic alkaloids occurs above pH 7.5, while acid degradation accelerates below pH 3.0. The addition of 0.2% w/v polysorbate 80 or 0.5% w/v sodium bisulfite is used only after compatibility screening, because sulfite antioxidants can produce adducts with the phenolic fractions of sophora root. Filtration through a 0.22 µm PVDF membrane filter followed by terminal autoclaving at 121 °C for 15 min is standard for aqueous injectables; the pre-filtration bioburden limit is 10 CFU/100 mL by Ph. Eur. 2.6.12 or USP <61>. The final product is tested for bacterial endotoxins by USP <85> with an acceptance threshold of 0.5 EU/mg of herbal solids, sub-visible particles by USP <788> for large-volume parenterals or the harmonised light obscuration method, and sterility by Ph. Eur. 2.6.1. Because raw herbal powder contains spores and endotoxins from soil-borne plant material, published data for complete depyrogenation of this specific configuration is limited; validation of the extraction and sterile filtration sequence is required on a batch-specific basis. The terminal injectable product is filled into 10 mL or 50 mL Type I glass vials under nitrogen if oxidation-sensitive markers are present. Any injectable formulation derived from this API must comply with the marketing authorisation dossier requirements of the target jurisdiction, including VICH GL18 residual solvent testing when extraction solvents other than water are used.

Feed premix manufacture from the veterinary powder API is constrained not by dissolution but by the statistical capability of dry mixing and carryover control in medicated feed lines. The standard approach is a two-stage dilution: a 1:50 intermediate premix is produced in a 200 kg ribbon blender by layering the raw powder between two equal portions of ground corn or wheat bran carrier, followed by a final 1:20 dilution into the target complete feed to achieve a final active concentration typically between 100 mg/kg and 2,000 mg/kg dry matter. The mixing time in a horizontal paddle mixer at 30 rpm is set by sampling 10 points per batch and analysing marker alkaloid recovery by Ph. Eur. 2.2.29 HPLC; a coefficient of variation below 5.0% is required under ISO 6497 sampling guidelines for animal feeding stuffs. The raw powder’s angle of repose above 40° prohibits direct addition to feed without intermediate mixing because segregation into fines occurs during screw conveying. Carryover is controlled by batching sequence: the medicated premix is run after a non-medicated flush batch of 5% of blender working volume; recovery of the alkaloid marker in the flush batch is monitored to a limit of 1% of the intended dose to avoid cross-contamination under GMP+ BA2 or ISO 22000:2018 feed safety management systems. The terminal premix is packed in 25 kg multi-wall paper sacks with inner polyethylene liners; labelling follows the target jurisdiction’s veterinary premix regulatory format. Premix batches are not dried after mixing; incoming moisture is controlled at ≤5.0% by USP <921> to prevent mould growth during storage. Homogeneity data must be generated on each new batch of raw powder because batch-to-batch variation in particle size and bulk density from the botanical source can shift the required mixing time by 20–30%.

Drinking Water Solubility Limits and pH Control in 1:2000 Stock Solutions

In drinking water administration for poultry and swine, the API must be presented as a concentrated stock solution because direct addition of raw powder to header tanks causes nozzle clogging. The stock solution is usually prepared at 1:100 w/v by dispersing the milled powder in deionized water at 40–50 °C under high-shear mixing at 3,000 rpm for 30 minutes, followed by pH adjustment to 4.5–5.5 with citric acid. The acidic pH improves the solubilisation of alkaloid markers, but it also increases the extraction of pectic polysaccharides from the herb matrix; for this reason the solution is clarified through a 50 µm in-line filter before entering the dosing pump. The stock solution is then diluted at 1:2,000 in the drinking water line, giving a final concentration of 0.05% w/v total solids. Above 0.1% w/v total solids, visible sedimentation occurs within 12 hours, and the insoluble particles settle in low-flow zones of the drinking system. Continuous agitation at 50–100 rpm is required for the stock tank; the final diluted solution is used within 24 hours to limit microbial proliferation. The solution is not sterile; total aerobic microbial count is controlled below 10⁴ CFU/g in the raw powder by Ph. Eur. 2.6.12 or USP <61>, and the stock solution is protected from direct sunlight to reduce photodegradation of alkaloid markers. Terminal solution is packaged as 1 L, 5 L, or 25 L HDPE jerry cans with tamper-evident closures. The pH of the final diluted solution is not the sole specification; the pH of the stock solution and the dilution ratio are both controlled because the buffering capacity of drinking water varies across farms. Published data on the solubility limit of the specific Maxing Kushen marker set in hard water is limited.

Fluid-Bed Granulation of Hydroalcoholic Herb Extracts Below 60 °C to Preserve Alkaloid Markers

Granules for oral suspension or sachet administration are produced by wet granulation in a fluid-bed processor equipped with a 500 L product bowl and a bottom-spray Wurster insert. The binder solution is prepared as 5% w/w polyvinylpyrrolidone K30 in purified water or a 30% w/w aqueous ethanol mixture when the powdered API has high resin content; the binder-to-powder ratio is typically 1:10 w/w for the raw herbal powder. The inlet air temperature is set to 55–60 °C, the product temperature is maintained at 38–42 °C, and the spray rate is adjusted to 150–250 g/min to avoid over-wetting and defluidisation. After spraying, the granules are dried to a loss-on-drying value of 2.5–4.0% by USP <731>; lower moisture causes excessive fines, while higher moisture causes blocking of the final sieve. The dried granulate is passed through a 1.0 mm sieve, and the fraction between 0.125 mm and 0.850 mm is selected as the saleable granule cut; fines below 0.125 mm are reworked at a level not exceeding 10% of the batch to avoid over granulation. Bulk density by Ph. Eur. 2.9.34 is specified between 0.50 g/mL and 0.65 g/mL for consistent volumetric dosing scoops. The final granules are packaged in 100 g or 500 g foil-laminated sachets and are reconstituted as an oral suspension at 1:10 w/v in water for farm use. Granulation improves flowability compared with raw powder, but it does not alter the basic alkaloid marker content if the product temperature does not exceed 42 °C; above 60 °C product temperature, batch-to-batch marker loss has been reported in comparable herbal matrices. Full stability data for this specific configuration is limited, so a conservative drying profile is used.

When individual animal treatment calls for direct oral powder administration, the raw veterinary powder API is used without granulation or compression. The powder is milled to pass 80 mesh (0.180 mm) by ISO 2591-1:2008 sieve analysis, filled into 100 g or 250 g amber glass or HDPE jars, and supplied with a dosing scoop calibrated to deliver 5 g or 10 g of powder. The powder is mixed into a small amount of feed or water immediately before administration to avoid separation. The primary risk in direct powder use is the variation in scoop fill caused by powder density changes; the user is instructed to fill the scoop level and to tap twice, which reduces the fill weight standard deviation to below 7% in field observations. The bulk powder is required to meet a microbial limit of 10⁴ CFU/g total aerobic microbial count and 10² CFU/g yeasts and moulds by Ph. Eur. 2.6.12 or USP <61>, and the elemental impurities specification follows ICH Q3D for veterinary products. Moisture is limited to 5.0% w/w by USP <921>, and the powder is stored below 25 °C and 60% relative humidity in closed containers. The absence of a manufacturing granulation step means the particle size distribution of the incoming botanical material directly affects the dose reproducibility; blending of batches is performed only after confirmation that the bulk density difference between lots is below 10% to avoid layering in the final container. Direct powder is not suitable for injectable or ophthalmic use.